Parkman Healthcare Partners LLC Grows Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Parkman Healthcare Partners LLC increased its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 30.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 241,575 shares of the biopharmaceutical company's stock after purchasing an additional 56,547 shares during the quarter. Intra-Cellular Therapies makes up approximately 2.3% of Parkman Healthcare Partners LLC's portfolio, making the stock its 11th biggest position. Parkman Healthcare Partners LLC owned approximately 0.23% of Intra-Cellular Therapies worth $17,676,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Avior Wealth Management LLC lifted its stake in Intra-Cellular Therapies by 3.0% in the third quarter. Avior Wealth Management LLC now owns 4,473 shares of the biopharmaceutical company's stock valued at $327,000 after buying an additional 131 shares during the last quarter. EFG Asset Management North America Corp. raised its stake in shares of Intra-Cellular Therapies by 0.5% during the second quarter. EFG Asset Management North America Corp. now owns 34,452 shares of the biopharmaceutical company's stock worth $2,357,000 after purchasing an additional 163 shares during the last quarter. Assetmark Inc. raised its stake in shares of Intra-Cellular Therapies by 9.1% during the third quarter. Assetmark Inc. now owns 2,477 shares of the biopharmaceutical company's stock worth $181,000 after purchasing an additional 207 shares during the last quarter. State of New Jersey Common Pension Fund D raised its stake in shares of Intra-Cellular Therapies by 0.6% during the third quarter. State of New Jersey Common Pension Fund D now owns 35,673 shares of the biopharmaceutical company's stock worth $2,610,000 after purchasing an additional 223 shares during the last quarter. Finally, US Bancorp DE raised its stake in shares of Intra-Cellular Therapies by 3.3% during the third quarter. US Bancorp DE now owns 7,951 shares of the biopharmaceutical company's stock worth $582,000 after purchasing an additional 251 shares during the last quarter. Hedge funds and other institutional investors own 92.33% of the company's stock.

Insider Activity at Intra-Cellular Therapies

In related news, President Michael Halstead sold 22,869 shares of the business's stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $89.12, for a total value of $2,038,085.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.60% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Piper Sandler upgraded Intra-Cellular Therapies from a "neutral" rating to an "overweight" rating and upped their price target for the stock from $68.00 to $92.00 in a research note on Friday, September 6th. Needham & Company LLC restated a "buy" rating and set a $100.00 price target on shares of Intra-Cellular Therapies in a research note on Wednesday, October 30th. The Goldman Sachs Group dropped their price objective on Intra-Cellular Therapies from $77.00 to $74.00 and set a "neutral" rating on the stock in a report on Thursday, August 8th. UBS Group dropped their price objective on Intra-Cellular Therapies from $83.00 to $79.00 and set a "neutral" rating on the stock in a report on Thursday, August 8th. Finally, Morgan Stanley upped their price objective on Intra-Cellular Therapies from $92.00 to $95.00 and gave the stock an "overweight" rating in a report on Friday, October 11th. Two investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $97.23.

Intra-Cellular Therapies Stock Performance

Intra-Cellular Therapies stock traded up $0.64 during midday trading on Wednesday, reaching $85.95. 427,281 shares of the company were exchanged, compared to its average volume of 841,988. The company has a market capitalization of $9.11 billion, a price-to-earnings ratio of -98.06 and a beta of 0.95. The firm's 50-day simple moving average is $80.67 and its 200-day simple moving average is $75.83. Intra-Cellular Therapies, Inc. has a 1 year low of $58.92 and a 1 year high of $93.45.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.07). The company had revenue of $175.40 million for the quarter, compared to analysts' expectations of $172.30 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The company's revenue for the quarter was up 39.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.25) EPS. On average, analysts forecast that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.